TNF Inhibitor denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your TNF Inhibitor as Not FDA-Approved — and Why You Can Appeal

A "not FDA-approved" denial from Humana typically signals one of two situations: (1) the specific TNF inhibitor prescribed is being used for an indication — a diagnosis — that is not listed on its FDA-approved label (sometimes called "off-label" use), or (2) there is a coding or administrative mismatch between the diagnosis submitted on the claim and the approved indications on file. True off-label use of TNF inhibitors does occur in clinical practice for certain conditions where evidence supports it, but coverage for off-label use varies significantly by plan.

## Why This Is Appealable

If your use is actually on-label — meaning your diagnosis matches an FDA-approved indication on the prescribing label — then the denial may reflect a documentation or coding error that can be corrected administratively or through appeal. If the use is genuinely off-label, many plans are still required to cover off-label use when it is supported by recognized compendia (such as Drugdex or NCCN Drugs & Biologics compendium) or by peer-reviewed medical literature and accepted clinical practice — consult your prescriber about whether compendium support applies in your situation. Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review and, if denied, an independent external review by a certified IRO. The external review window is generally within approximately four months of denial. Expedited review is available when delay poses serious clinical risk.

## The Appeal Process and Timeline

1. Review the denial letter carefully: confirm whether Humana is citing off-label use, a specific diagnosis code issue, or a drug-indication mismatch. 2. Check the FDA-approved prescribing label: obtain the current label and identify whether your diagnosis corresponds to an approved indication. 3. File an internal appeal: include the prescriber's letter and supporting documentation within the deadline stated in the denial letter. 4. If off-label: ask your prescriber whether the use appears in a recognized compendium or major peer-reviewed guidelines — this is a specific coverage trigger under many plans. 5. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• FDA-approved prescribing label: the current full prescribing information identifying all approved indications — confirm where your diagnosis falls.
• Diagnosis documentation: chart notes, specialist letters, and diagnostic records clearly establishing your diagnosis using the terminology and codes that align with the label indication.
• Prescriber's medical-necessity and indication letter: your physician should state the specific indication being treated, confirm whether it is on-label, and if off-label, cite the recognized compendia or guideline basis for the use.
• Compendium or guideline references (if off-label): your prescriber can reference the applicable specialty society guideline or recognized drug compendium supporting the use.
• Humana's coverage policy for off-label biologics: request this policy to understand the evidentiary standard Humana applies.

## Criteria-Mapping Structure

| Humana's Criterion | Your Response | |---|---| | FDA-approved indication confirmed | [Label indication; matching diagnosis in chart] | | If off-label: compendium or guideline support | [Prescriber citation; specific compendium or society guideline] | | Clinical necessity for this specific patient | [Prescriber letter; chart documentation] |

When the diagnosis genuinely matches an approved indication, these denials often resolve quickly once documentation is clarified and resubmitted.